LINC02506

Across TCGA pan-cancer cohorts, LINC02506 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LINC02506’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LINC02506 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02506 is over-expressed in tumor, although a few such as KIRC and COAD show the opposite, repressed pattern.

LIHC, BRCA, and KIRC are the cancer types where LINC02506 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02506 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+1.563	<.001	6	view →
BRCA	All	All	+0.220	.030	4	view →
KIRC	Male	All	−0.445	.001	3	view →
LUAD	All	All	+0.234	.038	3	view →
COAD	Male	II,III,IV	−0.116	.013	3	view →
THCA	Male	III,IV	−0.111	.033	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

LINC02506–LIHC

Open the LIHC breakdown →